T Kalland

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Physiology

Living Beings

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Søgaard M; Ohlsson L; Kristensson K; Rosendahl A; Sjoberg A; Forsberg G; Kalland T; Dohlsten M
Treatment with tumor-reactive Fab-IL-2 and Fab-staphylococcal enterotoxin A fusion proteins leads to sustained T cell activation, and long-term survival of mice with established tumors.
Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
Srinivas U; Dohlsten M; Kalland T; Lundblad A
Staphylococcal enterotoxin-A-induced in-vitro adhesion of HL-60 cells to endothelial cells involves both selectin and integrin families of cell adhesion molecules.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of T Kalland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

1999: Søgaard M; Ohlsson L; Kristensson K; Rosendahl A; Sjoberg A; Forsberg G; Kalland T; Dohlsten M
Treatment with tumor-reactive Fab-IL-2 and Fab-staphylococcal enterotoxin A fusion proteins leads to sustained T cell activation, and long-term survival of mice with established tumors.
International journal of oncology 1999;15(5):873-82.
1999: Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
International journal of cancer. Journal international du cancer 1999;80(1):138-44.
1998: Srinivas U; Dohlsten M; Kalland T; Lundblad A
Staphylococcal enterotoxin-A-induced in-vitro adhesion of HL-60 cells to endothelial cells involves both selectin and integrin families of cell adhesion molecules.
Scandinavian journal of immunology 1998;48(2):127-35.
1998: Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(11):5309-13.
1998: Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
International journal of cancer. Journal international du cancer 1998;76(2):274-83.
1998: Newton D W; Dohlsten M; Lando P A; Kalland T; Olsson C; Kotb M
MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma.
International journal of molecular medicine 1998;1(1):157-62.
1998: Tötterman T H; Gidlöf C; Ragnarsson L; Högbom E; Lindeberg M; von der Lehr N; Einarsson A; Soegaard M; Kristensson K; Kalland T; Dohlsten M
Targeted superantigens for immunotherapy of haematopoietic tumours.
Vox sanguinis 1998;74 Suppl 2():483-7.
1997: Rosendahl A; Hansson J; Antonsson P; Sékaly R P; Kalland T; Dohlsten M
A mutation of F47 to A in staphylococcus enterotoxin A activates the T-cell receptor Vbeta repertoire in vivo.
Infection and immunity 1997;65(12):5118-24.
1997: Krull F; Holzer U; Ihle J; Bethge W; Fierlbeck G; Kalland T; Dohlsten M; Niethammer D; Dannecker G E
Superantigen-induced lysis of melanoma cells.
Melanoma research 1997;7(3):214-22.
1997: Svensson L A; Schad E M; Sundström M; Antonsson P; Kalland T; Dohlsten M
Staphylococcal enterotoxins A, D, and E. Structure and function, including mechanism of T-cell superantigenicity.
Preparative biochemistry & biotechnology 1997;27(2-3):111-41.
1997: Giantonio B J; Alpaugh R K; Schultz J; McAleer C; Newton D W; Shannon B; Guedez Y; Kotb M; Vitek L; Persson R; Gunnarsson P O; Kalland T; Dohlsten M; Persson B; Weiner L M
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1994-2007.
1997: Litton M J; Dohlsten M; Hansson J; Rosendahl A; Ohlsson L; Kalland T; Andersson J; Andersson U
Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
The American journal of pathology 1997;150(5):1607-18.
1997: Antonsson P; Wingren A G; Hansson J; Kalland T; Varga M; Dohlsten M
Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(9):4245-51.
1997: Belfrage H; Dohlsten M; Hedlund G; Kalland T
Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment.
Cancer immunology, immunotherapy : CII 1997;44(2):77-82.
1997: Thibodeau J; Dohlsten M; Cloutier I; Lavoie P M; Bjork P; Michel F; Léveillé C; Mourad W; Kalland T; Sékaly R P
Molecular characterization and role in T cell activation of staphylococcal enterotoxin A binding to the HLA-DR alpha-chain.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(8):3698-704.
1997: Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck N G; Litton M J; Kalland T; Dohlsten M
Genetically engineered superantigens as tolerable antitumor agents.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(6):2489-94.
1997: Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman T H
A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Blood 1997;89(6):2089-97.
1997: Parra E; Varga M; Hedlund G; Kalland T; Dohlsten M
Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding.
Molecular and cellular biology 1997;17(3):1314-23.
1997: Labuda T; Parra E; Hedlund G; Kalland T; Dohlsten M
The tumour associated cell surface antigen A6H is costimulatory for human CD4+ but not CD8+ T cells.
Immunology 1997;90(2):236-43.
1997: Belfrage H; Dohlsten M; Hedlund G; Kalland T
Prevention of superantigen-induced down-regulation of T-cell mediated cytotoxic activity by IL-2 in vivo.
Immunology 1997;90(2):183-8.
1997: Holzer U; Orlikowsky T; Zehrer C; Bethge W; Dohlsten M; Kalland T; Niethammer D; Dannecker G E
T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.
Immunology 1997;90(1):74-80.
1997: Parra E; Wingren A G; Hedlund G; Kalland T; Dohlsten M
The role of B7-1 and LFA-3 in costimulation of CD8+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(2):637-42.
1997: Sundstedt A; Höiden I; Rosendahl A; Kalland T; van Rooijen N; Dohlsten M
Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(1):180-6.
1996: Zehrer C; Beck J; Gekeler V; Ihle J; Holzer U; Dohlsten M; Kalland T; Niethammer D; Dannecker G E
Superantigen-mediated cellular cytotoxicity is dependent on antigen expression, but independent of the P-glycoprotein multidrug resistance phenotype.
British journal of haematology 1996;95(3):452-6.
1996: Newton D W; Dohlsten M; Olsson C; Segrén S; Lundin K E; Lando P A; Kalland T; Kotb M
Mutations in the MHC class II binding domains of staphylococcal enterotoxin A differentially affect T cell receptor Vbeta specificity.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(9):3988-94.
1996: Lando P A; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(7):2857-63.
1996: Søgaard M; Hansson J; Litton M J; Ohlsson L; Rosendahl A; Lando P A; Antonsson P; Kalland T; Dohlsten M
Antibody-targeted superantigens in cancer immunotherapy.
Immunotechnology : an international journal of immunological engineering 1996;2(3):151-62.
1996: Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Immune response during tumor therapy with antibody-superantigen fusion proteins.
International journal of cancer. Journal international du cancer 1996;68(1):109-13.
1996: Wingren A G; Björkdahl O; Labuda T; Björk L; Andersson U; Gullberg U; Hedlund G; Sjögren H O; Kalland T; Widegren B; Dohlsten M
Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release.
Cellular immunology 1996;169(2):226-37.
1996: Sundstedt A; Sigvardsson M; Leanderson T; Hedlund G; Kalland T; Dohlsten M
In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(3):979-84.
1996: Litton M J; Dohlsten M; Lando P A; Kalland T; Ohlsson L; Andersson J; Andersson U
Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
European journal of immunology 1996;26(1):1-9.
1996: Antonsson P; Hansson J; Kalland T; Lando P A; Ohlsson L; Schad E; Svensson A; Dohlsten M
Genetically engineered superantigens in experimental tumor therapy.
Springer seminars in immunopathology 1996;17(4):397-410.
1995: Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(21):9791-5.
1995: Dohlsten M; Lando P A; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
Immunotherapy of human colon cancer by antibody-targeted superantigens.
Cancer immunology, immunotherapy : CII 1995;41(3):162-8.
1995: Gidlöf C; Dohlsten M; Kalland T; Tötterman T H
Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(9):1534-42.
1995: Labuda T; Lando P; Björkdahl O; Kalland T; Vessella R; Hedlund G; Eriksson H; Sjögren H O; Dohlsten M
A novel co-stimulatory T cell antigen co-expressed on renal cell carcinoma.
International immunology 1995;7(9):1425-32.
1995: Belfrage H; Dohlsten M; Hedlund G; Kalland T
Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo.
Cancer immunology, immunotherapy : CII 1995;41(2):87-94.
1995: Holzer U; Bethge W; Krull F; Ihle J; Handgretinger R; Reisfeld R A; Dohlsten M; Kalland T; Niethammer D; Dannecker G E
Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells.
Cancer immunology, immunotherapy : CII 1995;41(2):129-36.
1995: Lando P A; Dohlsten M; Ohlsson L; Kalland T
Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.
International journal of cancer. Journal international du cancer 1995;62(4):466-71.
1995: Parra E; Varga M; Sigvardsson M; Hedlund G; Kalland T; Leanderson T; Sjögren H O; Dohlsten M
Costimulation of human CD4+ T cells with LFA-3 and B7 induce distinct effects on AP-1 and NF-kappa B transcription factors.
Journal of immunology (Baltimore, Md. : 1950) 1995;155(3):1132-40.
1995: Schad E M; Zaitseva I; Zaitsev V N; Dohlsten M; Kalland T; Schlievert P M; Ohlendorf D H; Svensson L A
Crystal structure of the superantigen staphylococcal enterotoxin type A.
The EMBO journal 1995;14(14):3292-301.
1995: Abrahmsén L; Dohlsten M; Segrén S; Björk P; Jonsson E; Kalland T
Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A.
The EMBO journal 1995;14(13):2978-86.
1995: Sundstedt A; Höidén I; Hansson J; Hedlund G; Kalland T; Dohlsten M
Superantigen-induced anergy in cytotoxic CD8+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(12):6306-13.
1995: Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker G E
Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Cancer research 1995;55(3):623-8.
1995: Wingren A G; Parra E; Varga M; Kalland T; Sjögren H O; Hedlund G; Dohlsten M
T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles.
Critical reviews in immunology 1995;15(3-4):235-53.
1994: Parra E; Wingren A G; Hedlund G; Björklund M; Sjögren H O; Kalland T; Sansom D; Dohlsten M
Costimulation of human CD4+ T lymphocytes with B7 and lymphocyte function-associated antigen-3 results in distinct cell activation profiles.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(6):2479-87.
1994: Sundstedt A; Dohlsten M; Hedlund G; Höidén I; Björklund M; Kalland T
Superantigens anergize cytokine production but not cytotoxicity in vivo.
Immunology 1994;82(1):117-25.
1994: Belfrage H; Bhiladvala P; Hedlund G; Dohlsten M; Kalland T
Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity.
Cancer immunology, immunotherapy : CII 1994;38(4):265-71.
1993: Parra E; Wingren A G; Hedlund G; Sjögren H O; Kalland T; Sansom D; Dohlsten M
Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules.
Scandinavian journal of immunology 1993;38(6):508-14.
1993: Akerblom E; Dohlsten M; Brynö C; Mastej M; Steringer I; Hedlund G; Lando P; Kalland T
Preparation and characterization of conjugates of monoclonal antibodies and staphylococcal enterotoxin A using a new hydrophilic cross-linker.
Bioconjugate chemistry 1993;4(6):455-66.
1993: Lando P A; Dohlsten M; Hedlund G; Brodin T; Sansom D; Kalland T
Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.
Immunology 1993;80(2):236-41.
1993: Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman T H
Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
Blood 1993;82(4):1230-8.
1993: Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
Immunology 1993;79(4):520-7.
1993: Wingren A G; Dahlenborg K; Björklund M; Hedlund G; Kalland T; Sjögren H O; Ljungdahl A; Olsson T; Ekre H P; Sansom D
Monocyte-regulated IFN-gamma production in human T cells involves CD2 signaling.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(3):1328-36.
1993: Dohlsten M; Sundstedt A; Björklund M; Hedlund G; Kalland T
Superantigen-induced cytokines suppress growth of human colon-carcinoma cells.
International journal of cancer. Journal international du cancer 1993;54(3):482-8.
1993: Kalland T; Dohlsten M; Abrahmsén L; Hedlund G; Björk P; Lando P A; Sundstedt A; Akerblom E; Lind P
Targeting of superantigens.
Cell biophysics 1993;22(1-3):147-64.
1993: Lando P A; Dohlsten M; Hedlund G; Akerblom E; Kalland T
T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.
Cancer immunology, immunotherapy : CII 1993;36(4):223-8.
1993: Hedlund G; Dohlsten M; Petersson C; Kalland T
Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells.
Cancer immunology, immunotherapy : CII 1993;36(2):89-93.
1993: Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando P A; Björklund M
Monoclonal antibodies and superantigens: a novel therapeutic approach.
Medical oncology and tumor pharmacotherapy 1993;10(1-2):37-47.
1992: Hansson J; Ericsson P O; Dohlsten M; Sjögren H O; Kalland T; Hedlund G
Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8+ CD45RC- subset and lyse MHC class II+ tumor cells.
Immunology letters 1992;34(3):229-36.
1992: Gjörloff A; Hedlund G; Kalland T; Sansom D; Fischer H; Trowsdale J; Sjögren H O; Dohlsten M
The LFA-3 adhesion pathway is differently utilized by superantigen-activated human CD4+ T-cell subsets.
Scandinavian journal of immunology 1992;36(2):243-50.
1992: Fischer H; Gjörloff A; Hedlund G; Hedman H; Lundgren E; Kalland T; Sjögren H O; Dohlsten M
Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(7):1993-8.
1991: Hedlund G; Dohlsten M; Herrmann T; Buell G; Lando P A; Segrén S; Schrimsher J; MacDonald H R; Sjögren H O; Kalland T
A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(12):4082-5.
1991: Dohlsten M; Hedlund G; Akerblom E; Lando P A; Kalland T
Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(20):9287-91.
1991: Lando P A; Hedlund G; Dohlsten M; Kalland T
Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A.
Cancer immunology, immunotherapy : CII 1991;33(4):231-7.
1991: Kalland T; Hedlund G; Dohlsten M; Lando P A
Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity.
Current topics in microbiology and immunology 1991;174():81-92.
1990: Fischer H; Hedlund G; Kalland T; Sjögren H O; Dohlsten M
Independent regulation of IFN-gamma and tumor necrosis factor by IL-1 in human T helper cells.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(11):3767-72.
1988: Dohlsten M; Kalland T; Sjögren H O; Carlsson R
Histamine inhibits interleukin 1 production by lipopolysaccharide-stimulated human peripheral blood monocytes.
Scandinavian journal of immunology 1988;27(5):527-32.
1987: Kalland T; Belfrage H; Bhiladvala P; Hedlund G
Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(11):3640-5.
1987: Belfrage H; Bhiladvala P; Kalland T
Functionally involved cell surface antigens on murine lymphokine activated killer cells.
Immunology letters 1987;14(4):293-8.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

T Kalland

Research Profile (preview)

Chemicals & Drugs

Physiology

Living Beings

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of T Kalland (preview)

All Publications